Silence Therapeutics plc (SLNC.F) Report Analysis
Corporate Events
Silence Therapeutics plc Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM
2022-06-03 12:23:00
Silence Therapeutics plc Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM. Venue: Marriott Marquis, New York City, New York, United States.
Silence Therapeutics plc Presents at H.C. Wainwright Global Investment Conference 2022, May-23-2022 07:00 AM
2022-05-18 11:00:00
Silence Therapeutics plc Presents at H.C. Wainwright Global Investment Conference 2022, May-23-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.
Silence Therapeutics plc - Shareholder/Analyst Call
2022-05-16 12:31:00
AGM
Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022
2022-05-16 12:31:00
Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022, at 09:00 Eastern Daylight. Location: The Westin Jersey City Newport 479 Washington Blvd Jersey City New Jersey United States Agenda: To approve the power conferred by this resolution shall expire (unless previously revoked or varied by the Company in general meeting) at the conclusion of the next Annual General Meeting of the Company or the date 15 months from the date of passing of this resolution, whichever is the earlier, save that the Company may before such expiry, revocation or variation make an offer or agreement which would or might require equity securities to be allotted after such expiry, revocation or variation and the Directors may allot equity securities pursuant to such offer or agreement as if the power hereby conferred had not expired or been revoked or varied. This power is in substitution for any and all powers previously conferred on the Directors under Section 570 of the Companies Act, but without prejudice to any allotment of equity securities made or agreed to be made pursuant to such powers.
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
2022-04-25 12:31:00
Silence Therapeutics plc announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (Hansoh") following the achievement of an undisclosed preclinical milestone. Silence and Hansoh entered a collaboration in October 2021 to develop siRNAs leveraging Silence's proprietary mRNAi GOLD platform for three undisclosed targets. Under the terms of the agreement, Silence has exclusive rights to the first two targets in all territories except the China region (Greater China, Hong Kong, Macau and Taiwan). Hansoh has the exclusive option to license rights to those two targets in the China region and global rights to the third target.
Silence Therapeutics plc Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 08:00 AM
2022-04-06 11:00:00
Silence Therapeutics plc Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 08:00 AM.
Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
2022-04-03 12:00:00
Silence Therapeutics plc presented detailed results from its phase 1 APOLLO trial that showed SLN360, an investigational siRNA, reduced levels of lipoprotein(a) (“Lp(a)”), an important genetic risk factor for heart disease, by up to 98% in healthy adults with high Lp(a). Findings from the “APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial” were presented during a Late Breaking Science Session at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22) and simultaneously published online in the Journal of the American Medical Association. The phase 1 APOLLO trial evaluated SLN360 in 32 adults at five medical centers in the U.S., UK and Netherlands. All participants had plasma concentrations at screening of Lp(a) =150 nmol/L with a median level of 224 nmol/L (75 nmol/L or less is considered normal). Individuals were randomly assigned to receive a single subcutaneous dose of SLN360 (30 mg, 100 mg, 300 mg or 600 mg) or placebo and were observed closely for the first 24 hours, then periodically assessed for 150 days. There were no serious safety concerns reported and the most common side effect was temporary redness at the injection site. Participants receiving 300 mg and 600 mg of SLN360 had up to 96% and 98% median reduction in Lp(a) levels, respectively, and median reductions of up to 71% and 81% from baseline persisted at 150 days. Those receiving a placebo saw no change in Lp(a) levels. The study follow-up period has been extended to 365 days to further assess the duration of action. Other efficacy measures included the effects of SLN360 on low-density lipoprotein cholesterol (LDL cholesterol) and apolipoprotein B (ApoB), both of which are associated with an increased risk of cardiovascular events. The highest doses of SLN360 reduced LDL cholesterol and ApoB by about 25%. Silence is evaluating SLN360 in the multiple-ascending dose portion of the APOLLO phase 1 study in patients with high Lp(a) that have a confirmed history of stable atherosclerotic cardiovascular disease (“ASCVD”). Silence plans to initiate the SLN360 phase 2 ASCVD study in the second half of 2022, pending regulatory discussions.
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022
2022-02-28 18:21:00
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022
2022-02-11 23:04:00
Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
2022-02-09 12:00:00
Silence Therapeutics plc announced positive topline results in its phase 1 single-ascending dose study of SLN360, an siRNA targeting lipoprotein(a) (“Lp(a)”), in healthy adults with high Lp(a). High Lp(a), defined as = 50 mg/dL (c.125nmol/L), affects approximately 20% of the world’s population and is a genetic risk factor for cardiovascular disease. There are no approved medicines that selectively lower Lp(a). SLN360 is a siRNA that is designed to lower Lp(a) production by targeting messenger RNA transcribed from the LPA gene. This phase 1 study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of SLN360 at escalating doses in 32 adults with plasma concentrations at screening of Lp(a) =150 nmol/L (approximately = 60 mg/dL) with no known cardiovascular disease. Individuals were randomly assigned to receive a single subcutaneous dose of SLN360 (30 mg, 100 mg, = 300 mg or = 600 mg) or placebo and were observed for up to 150 days. The primary safety objective was assessment of treatment-emergent adverse events. No clinically important safety concerns were identified. Low grade adverse events at the injection site were observed, most prominently at the highest dose. As expected, systemic exposures (PK) of SLN360 increased in a broadly dose-proportional manner. The key efficacy assessment was percent change from baseline in Lp(a). SLN360 reduced Lp(a) in a dose dependent manner from 46% up to a maximum of 98% with up to an 81% reduction persisting at 150 days. The study follow-up period has been extended from 150 days to 365 days to further assess the duration of action. Silence anticipates data from the extended follow-up period in the third quarter of 2022. Detailed results from the SLN360 phase 1 single-ascending dose study will be presented by principal investigator and Professor of Cardiovascular Medicine at the Cleveland Clinic, Steven E. Nissen, MD, at the American College of Cardiology (ACC) Annual Scientific Session & Expo on April 3, 2022. Patient enrollment continues in the multiple-ascending dose portion of the SLN360 phase 1 study in patients with high Lp(a) that have a confirmed history of stable atherosclerotic cardiovascular disease (“ASCVD”). Silence remains on-track to initiate the SLN360 phase 2 ASCVD study in the second half of 2022, pending regulatory discussions.
American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022
2022-01-26 12:00:00
American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022. Venue: Washington, District Of Columbia, United States.
Silence Therapeutics plc Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-03-2022 08:00 AM
2022-01-26 12:00:00
Silence Therapeutics plc Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-03-2022 08:00 AM. Venue: Washington, District Of Columbia, United States.
Silence Therapeutics plc Presents Additional Positive Data from the SLN124 Healthy Volunteer Study
2021-12-12 14:01:00
Silence Therapeutics plc presented additional positive data from the SLN124 healthy volunteer study at the 2021 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia (USA). SLN124, a siRNA targeting the liver expressed TMPRSS6 gene, is currently in development for iron loading anemia conditions, thalassemia and myelodysplastic syndrome (MDS). The phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study evaluated the safety and tolerability of SLN124 (1.0, 3.0 and 4.5 mg/kg doses) in 24 healthy volunteers. Pharmacokinetic parameters and pharmacodynamic biomarkers of iron metabolism were also measured to assess reduction in iron.
Silence Therapeutics plc has withdrawn its Shelf Registration dated October 15, 2021 in the amount of $300 million.
2021-11-30 00:00:00
Silence Therapeutics plc has withdrawn its Shelf Registration dated October 15, 2021 in the amount of $300 million. Security Name: Ordinary Shares
Silence Therapeutics Updates on AIM Delisting
2021-11-26 07:00:00
Silence Therapeutics plc provided a further update with respect to the cancellation of admission of its ordinary shares of nominal value £0.05 each (the "Ordinary Shares") to trading on AIM (the "AIM Delisting"), as originally announced on October 15, 2021. As previously announced, the last day of trading of the Company's Ordinary Shares on AIM will be November 29, 2021 and the proposed AIM Delisting will be effective from 7.00 a.m. (London time) on November 30, 2021. Silence will retain the listing of its American Depositary Shares, each representing three Ordinary Shares (the "ADSs"), on the Nasdaq Global Market ("Nasdaq") under the ticker symbol SLN. Following the AIM Delisting, the Company's ADSs will remain listed, and will only be tradeable, on Nasdaq.
Silence Therapeutics Delisting from AIM
2021-11-16 09:37:00
On October 15, 2021, Silence Therapeutics plc announced its intention to cancel the admission of its ordinary shares of nominal value £0.05 each trading on AIM, with effect from November 30, 2021. Shareholders approved the delisting on November 1, 2021. Last day of trading on AIM will be November 29, 2021. The company will retain its listing on the Nasdaq Global Market of American Depositary Shares, of which each represents three Ordinary Shares, under ticker symbol "SLN". The company expects Nasdaq to become the primary trading venue for its equity securities.
Silence Therapeutics plc Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM
2021-11-11 07:00:00
Silence Therapeutics plc Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.
Frazier Life Sciences Public Fund, managed by Frazier Management, L.L.C. acquired 3% stake in Silence Therapeutics plc (AIM:SLN) for approximately $20 million.
2021-11-05 00:00:00
Frazier Life Sciences Public Fund, managed by Frazier Management, L.L.C. acquired 3% stake in Silence Therapeutics plc (AIM:SLN) for approximately $20 million on November 5, 2021. Frazier Life Sciences Public Fund, managed by Frazier Management, L.L.C. completed the acquisition of 3% stake in Silence Therapeutics plc (AIM:SLN) on November 5, 2021.
Silence Therapeutics plc Approves Amendment to Articles of Association
2021-11-01 17:33:00
Silence Therapeutics plc at its general meeting held November 1, 2021, approved the amendment to the articles of association of the company.
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
2021-10-21 12:30:00
Silence Therapeutics plc announced it is hosting its R&D Day in New York City. During the event, Silence plans to showcase its proprietary mRNAi GOLD™ platform and current clinical programs, including SLN360 for cardiovascular disease due to high lipoprotein(a), or Lp(a), and SLN124 for thalassemia and myelodysplastic syndrome (MDS) as well as a newly added program in polycythemia vera (PV). Silence will also provide an update on its growing discovery pipeline and plans to deliver 2-3 INDs per year from 2023. SLN124 Program: New highlighted updates include: Plans to pursue new PV indication and start a phase 1 trial in the second half of 2022. FDA acceptance of the US IND in myelodysplastic syndrome (MDS). Enrollment continues in the two single-ascending dose studies for thalassemia and MDS. Silence anticipates topline data from both studies in the third quarter of 2022. Positive results from the healthy volunteer study reported in May 2021 accepted for poster presentation at the American Society of Hematology (ASH) Annual Meeting being held December 11-14, 2021. SLN360Program: New highlighted updates include: On-track to report top-line data in the single-ascending dose study in the first quarter of 2022. Key outcomes from the independent safety review committee meeting: Recommendation to extend follow-up period in the single-ascending dose study from 150 days to 365 days to fully assess the duration of action, which may be longer than initially anticipated based on preclinical modelling; and The therapeutic dose range has been established based on Cohorts 1-4 (optional Cohort 5 not needed) and study can now proceed to the multiple-ascending dose phase. On-track to initiate phase 2 development in the second half of 2022, pending regulatory discussions. mRNAi GOLD™Partnered Program Updates: AstraZeneca Collaboration for Cardiovascular, Renal, Metabolic and Respiratory Diseases: Continuing work with AstraZeneca to develop siRNAs for two undisclosed targets. On-track to initiate work on five targets within the first three years of the collaboration. Mallinckrodt Collaboration for Complement-Mediated Diseases: Progressing IND-enabling studies for SLN501 C3-targeting program and expect to initiate a phase 1 study in the first half of 2022. Developing siRNAs for two other undisclosed complement-mediated disease targets. Hansoh Collaboration: In addition to the two proprietary programs outlined above, Silence will work with Hansoh on a third undisclosed program which Hansoh has the option to license worldwide at the point of IND filing. As part of the Hansoh agreement, Hansoh made a $16 million upfront cash payment and Silence has the potential for up to $1.3 billion in additional milestones plus royalties tiered from low double-digit to mid-teens on Hansoh net product sales. Targeting 2-3 INDs per year from 2023: Silence remains on-track to deliver 2-3 INDs per year from 2023 through both its proprietary and partnered mRNAi GOLD™ platform programs. Key highlighted updates include: Expanded translational genomics efforts, contributing both to finding new, genetically validated disease-causing genes and continuously fine-tuning the siRNA design algorithm using machine learning; A fine-tuned drug discovery process; Aiming for a mixed-risk portfolio of validated and novel targets with projects at different stages of drug discovery ensuring multiple shots on goal.
Silence Announces Cancellation of Admission of Its Ordinary Shares to Trading on AIM
2021-10-15 11:05:00
Silence Therapeutics plc ("Silence" or "the Company") announcedthe Company's intention to cancel the admission of its ordinary shares of nominal value £0.05 each (the "Ordinary Shares") to trading on AIM (the "AIM Delisting"), subject to shareholder approval, with effect from November 30, 2021. Subject to shareholder approval, the Company's last day of trading on AIM will be 29 November 2021. Silence will retain the listing on the Nasdaq Global Market (“Nasdaq”) of American Depositary Shares, each representing three Ordinary Shares (the “ADSs”), under ticker symbol “SLN”. The Company expects Nasdaq to become the primary trading venue for its equity securities. Existing holders of ADSs not also holding Ordinary Shares do not need to take any action in relation to the AIM Delisting; and the posting of a circular to shareholders (the “Circular”) which contains further information on the AIM Delisting and the process to deposit Ordinary Shares for delivery of ADSs and notice of a general meeting to be held on November 1, 2021 at 2.00 p.m. (London time) (the “General Meeting”) at which shareholder approval will be sought, inter alia, for the AIM Delisting. The Board has decided to implement the AIM Delisting for the following reasons: The AIM Delisting is expected to further enhance the liquidity of trading in the Company’s securities by combining on Nasdaq the volume of transactions from both Nasdaq and AIM. Having securities solely listed on Nasdaq, rather than dual-listed on Nasdaq and AIM as is the case at present, is expected to increase the willingness of US-based investors to invest in the Company’s securities. A Nasdaq-only listing structure provides for a streamlined operation that showcases the global nature of the Company’s scope and places it more clearly within the ranks of international biotechnology companies that are its true peers. The cost of complying with the AIM Rules for Companies is incremental to that for complying with the Nasdaq market rules and the Company sees advantages in reducing its cost base as it progresses its clinical programmes and commercial strategy., Internal financial and legal staff time spent on compliance with the AIM Rules for Companies is incremental to that required for compliance with the Nasdaq market rules and ADSs representing the Company’s Ordinary Shares will remain tradeable on Nasdaq.
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD Platform
2021-10-15 11:00:00
Silence Therapeutics plc and Hansoh Pharmaceutical Group Company Limited announced a collaboration to develop siRNAs for three undisclosed targets leveraging Silence’s proprietary mRNAi GOLD platform. Under the terms of the agreement, Hansoh will have the exclusive option to license rights to the first two targets in Greater China, Hong Kong, Macau and Taiwan following the completion of phase 1 studies. Silence will retain exclusive rights for those two targets in all other territories. Silence will be responsible for all activities up to option exercise and will retain responsibility for development outside the China region post phase 1 studies. Hansoh will also have the exclusive option to license global rights to a third target at the point of IND filing. Hansoh will be responsible for all development activities post option exercise for the third target.
Silence Therapeutics plc, Special/Extraordinary Shareholders Meeting, Nov 01, 2021
2021-10-15 06:05:00
Silence Therapeutics plc, Special/Extraordinary Shareholders Meeting, Nov 01, 2021, at 14:00 Coordinated Universal Time. Location: 72 Hammersmith 72 Hammersmith Road, London W14 London United Kingdom Agenda: To discuss AIM Delisting; and the intention to file with the U.S. Securities and Exchange Commission a shelf registration statement on Form F-3 (the "Registration Statement") pursuant to which the Company may offer and sell up to $300,000,000 of its Ordinary Shares in the form of ADSs including the intention to enter into a sales agreement.
Silence Therapeutics plc has filed a Shelf Registration in the amount of $300 million.
2021-10-15 00:00:00
Silence Therapeutics plc has filed a Shelf Registration in the amount of $300 million. Security Name: Ordinary Shares
Silence Therapeutics plc has filed a Follow-on Equity Offering in the amount of $100 million.
2021-10-15 00:00:00
Silence Therapeutics plc has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Transaction Features: At the Market Offering
Silence Therapeutics plc Presents at Chardan's 5th Annual Genetic Medicines Conference, Oct-05-2021 08:30 AM
2021-09-28 06:00:00
Silence Therapeutics plc Presents at Chardan's 5th Annual Genetic Medicines Conference, Oct-05-2021 08:30 AM.
OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC, 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep 26, 2021 through Sep 29, 2021
2021-09-04 15:00:00
OLIGONUCLEOTIDE THERAPEUTICS SOCIETY INC, 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep 26, 2021 through Sep 29, 2021.
Silence Therapeutics plc Presents at 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep-26-2021
2021-09-04 15:00:00
Silence Therapeutics plc Presents at 17th Annual Meeting of the Oligonucleotide Therapeutics Society, Sep-26-2021 . Speakers: Marie Wikstrom Lindholm, Senior VP & Head of Molecular Design.
Silence Therapeutics plc Appoints John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development
2021-09-01 11:00:00
Silence Therapeutics plc announced the appointment of John Strafford, Ph.D., to the newly created role of Senior Vice President, Business Development, Alliance Management and New Product Development, effective immediately. John joined Silence in 2018 and has served as Vice President, Head of Business Development and member of the Executive Leadership Team since 2019. In his new role, John will continue to drive all business development and alliance management activities as well as lead the new product development function, helping to define the future commercial strategy for the Company's proprietary mRNAi GOLD development pipeline.
Silence Therapeutics plc Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11:45 AM
2021-08-25 06:00:00
Silence Therapeutics plc Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11:45 AM. Venue: New Windsor, United States.
Silence Therapeutics plc Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM
2021-08-25 06:00:00
Silence Therapeutics plc Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.
Chardan Capital Markets, LLC, Chardan's 5th Annual Genetic Medicines Conference, Oct 04, 2021 through Oct 05, 2021
2021-08-24 14:20:00
Chardan Capital Markets, LLC, Chardan's 5th Annual Genetic Medicines Conference, Oct 04, 2021 through Oct 05, 2021.
Silence Therapeutics plc - Special Call
2021-08-12 06:00:00
To discuss progress of SLN360 and SLN124 clinical programs as well as its broader pipeline
Silence Therapeutics plc to Report Q2, 2021 Results on Aug 12, 2021
2021-07-15 06:00:00
Silence Therapeutics plc announced that they will report Q2, 2021 results on Aug 12, 2021
Silence Therapeutics plc, H1 2021 Earnings Call, Aug 12, 2021
2021-07-15 06:00:00
Silence Therapeutics plc, H1 2021 Earnings Call, Aug 12, 2021
Fundamental Summary
Silence Therapeutics's recently released results from Q4 indicate that Silence Therapeutics is performing reasonably well and on par with its peers. This typically translates into the stock performing on par with market performance for the upcoming quarter. Overall, Silence Therapeutics's growth and income factors are trending positively, and we, therefore, give Silence Therapeutics an overall grade of 70 and a HOLD recommendation.
Silence Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was GBP 5.72 million compared to GBP 3.14 million a year ago. Net loss was GBP 7.68 million compared to GBP 8.42 million a year ago. Basic loss per share from continuing operations was GBP 0.086 compared to GBP 0.097 a year ago.
Sector Overview
Silence Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Silence Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -70.0 | -38.8% | 69 | |
| Net Cashflow | -8.0 | 55.2% | 68 | |
| Capital Expenditure | -0.0 | 93.3% | 72 | |
| Asset Turnover | 0.0 | 0.0% | 69 | |
| Free Cashflow | 0.0 | 108.8% | 66 |
* All values are TTM
The below chart reflects Silence Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Silence Therapeutics's peer average final assessment score stands on 61.0, Silence Therapeutics's score is 70.
- SLNC.F
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Silence Therapeutics's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Silence Therapeutics's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.
5D MA
5.0
50D MA
7.4
200D MA
6.56
MACD
-0.73
RSI
53.64
STOCH
4.09
Balance Sheet Analysis
Assets and Equity stood out as the most significant drivers of Silence Therapeutics's balance sheet strength. The company's assets section could set high expectations for Silence Therapeutics's future attractiveness, as they went to 46.1, which is a 53.5% change from the last period. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Consequently, their asset movement received a grade of 71. Also, Silence Therapeutics did a great job related to equity this period, which stood at 20.9, representing a -23.0% change. Companies in the same sector and market capitalization will usually be affected by up to 0.3 percent by this parameter. This performance is significantly more impressive than its peers and competitors. Consequently, their equity movement received a grade of 69. However, one discouraging result, Liabilities, stood out. Silence Therapeutics's liabilities stood at 25.2 in the current filing, which represents a 780.3% change from the previous report. These liabilities metrics show that management has been unsuccessful in encouraging healthy growth while managing liabilities. Therefore, we rated their liabilities movement with a score of 58. Therefore, it received a score of 66.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 46.1 | 53.5% | 71 |
| Liabilities | 25.2 | 780.3% | 58 |
| Price to Book | 13.3 | 529.0% | 59 |
| Cash & Equivalents | 13.5 | 17.4% | 63 |
| Equity | 20.9 | -23.0% | 69 |
The below chart describes Silence Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Silence Therapeutics received a balance sheet score of 66, the average of its peers stands on 69.0.
- SLNC.F
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 0 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 1 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 2 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 3 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 4 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 5 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 6 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 7 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 8 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 9 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 10 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 11 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 12 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 13 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 14 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 15 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 16 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 17 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 18 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 19 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 20 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 21 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 22 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 23 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 24 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 25 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 26 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 27 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 28 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 29 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 30 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 31 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 32 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 33 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 34 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 35 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 36 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 37 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 38 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 39 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 40 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 41 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 42 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 43 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 44 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 45 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 46 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 47 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 48 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 49 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 50 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 51 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 52 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 53 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 54 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 55 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 56 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 57 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 58 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 59 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 60 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 61 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 62 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 63 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 64 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 65 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 66 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 67 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 68 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 69 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 70 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 71 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 72 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 73 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 74 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 75 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 76 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 77 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 78 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 79 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 80 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 81 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 82 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 83 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 84 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 85 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 86 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 87 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 88 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 94 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 96 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 97 | 1 |
Income Statement Analysis
Two metrics jump up as the most significant positive drivers of the income statement's strength in Silence Therapeutics's recent report: Revenue Efficiency and Return Factors. Silence Therapeutics reported highly encouraging numbers for its revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 12.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. Consequently, their revenue efficiency received a grade of 83. Also, Silence Therapeutics's reported return on equity (ROE) ratio was -70.0, representing a change of -38.8%. Its return factor metrics are even more remarkable when compared to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 69. However, one discouraging result, EBITDA, stood out. Silence Therapeutics reported concerning EBITDA this period. At filing, EBITDA was reported as -22.3, representing -11.7% change from the previous period. This parameter coud affect companies in the same industry and market capitalization by up to 22.5%. Silence Therapeutics appears to be headed in the wrong direction in terms of EBITDA momentum, likely due to insufficient capital controls and a weaker than expected overall financial performance. Its EBITDA movement, therefore, received a grade of 64. As the companie's management is doing an excellent job managing the critical metrics, the income statement was given a score of 72.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -22.3 | -11.7% | 64 |
| Total Revenues | 0.2 | 0.0% | 83 |
| Return on Equity | -70.0 | -38.8% | 69 |
The below chart describes Silence Therapeutics's performance as reflected on its income statement with respect to its peers. While Silence Therapeutics received a income statement score of 72 , the average of its peers stands on 65.0.
- SLNC.F
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 0 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 1 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 2 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 3 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 4 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 5 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 6 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 7 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 8 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 9 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 10 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 11 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 12 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 13 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 14 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 15 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 16 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 17 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 18 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 19 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 20 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 21 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 22 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 23 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 24 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 25 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 26 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 27 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 28 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 29 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 30 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 31 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 32 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 33 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 34 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 35 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 36 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 37 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 38 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 39 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 40 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 41 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 42 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 43 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 44 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 45 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 46 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 47 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 48 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 49 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 50 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 51 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 52 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 53 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 54 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 55 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 56 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 57 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 58 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 59 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 60 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 61 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 62 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 63 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 64 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 65 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 66 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 67 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 68 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 69 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 70 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 71 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 72 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 73 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 74 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 75 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 76 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 77 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 78 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 79 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 80 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 81 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 82 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 83 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 84 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 85 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 86 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 87 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 88 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 94 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 96 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 97 | 1 |
Cash Flow Analysis
Overall, Silence Therapeutics's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Silence Therapeutics's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. Silence Therapeutics recorded CapEx of -0.0, which represents 93.3% change from the previous report. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. The company's CapEx movement, therefore, received a grade of 72. Also, Silence Therapeutics's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Silence Therapeutics recorded asset turnover of 0.0, which represents a 0.0% change from the previous report. This metric might have a 7.8 percent impact on companies in the same industry and with the same market capitalization. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. Correspondingly, their asset turnover movement received a grade of 69. That said, one metric, Free Cash flow, stood out as strongly negative. Silence Therapeutics did a poor job related to generating and maintaining strong free cash flow this period, which stood at 0.0, representing a 108.8% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 3.4 percent by this parameter. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Consequently, their free cash flow movement received a grade of 66. Their cash flow, therefore, earned a score of 69.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -8.0 | 55.2% | 68 |
| Capital Expenditure | -0.0 | 93.3% | 72 |
| Asset Turnover | 0.0 | 0.0% | 69 |
| Free Cashflow | 0.0 | 108.8% | 66 |
The below chart describes Silence Therapeutics's performance as reflected on its cash flow with respect to its peers. While Silence Therapeutics received a cash flow score of 69, the average of its peers stands on 59.0.
- SLNC.F
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 0 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 1 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 2 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 3 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 4 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 5 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 6 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 7 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 8 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 9 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 10 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 11 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 12 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 13 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 14 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 15 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 16 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 17 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 18 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 19 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 20 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 21 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 22 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 23 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 24 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 25 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 26 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 27 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 28 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 29 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 30 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 31 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 32 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 33 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 34 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 35 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 36 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 37 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 38 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 39 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 40 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 41 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 42 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 43 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 44 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 45 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 46 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 47 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 48 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 49 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 50 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 51 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 52 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 53 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 54 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 55 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 56 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 57 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 58 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 59 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 60 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 61 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 62 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 63 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 64 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 65 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 66 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 67 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 68 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 69 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 70 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 71 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 72 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 73 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 74 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 75 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 76 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 77 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 78 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 79 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 80 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 81 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 82 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 83 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 84 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 85 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 86 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 87 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 88 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 94 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 96 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.